PathAI vs Proscia (2026)
Both sell a cleared image management platform for primary diagnosis with their own AI labeled research use only, so the choice turns on scanners, deployment and ownership. PathAI's AISight Dx is 510(k) cleared (K243391) with four named scanners and runs PathAI's algorithms beside partners'; in May 2026 PathAI agreed to be acquired by Roche. Proscia's Concentriq AP-Dx is cleared (K230839, and K261380 in August 2026, which added cloud deployment and a change control plan), supports more than 45 scanners and remains independent.
- You run MASH trials, where AIM-MASH AI Assist is qualified by the EMA and the FDA.
- Your laboratory network already uses AISight, as Labcorp and MedStar Health do.
- Roche ownership fits your diagnostics relationships.
- Scanner choice matters: more than 45 scanners are supported.
- You want a change control plan and cloud deployment named in the clearance itself.
- Your security review asks for SOC 2 Type II, ISO 27001 and ISO 13485, which Proscia names.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. PathAI and Proscia are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
| Fact | PathAI | Proscia |
|---|---|---|
| Primary category | Digital Pathology AI | Digital Pathology AI |
| Founded | 2016 | 2014 |
| Headquarters | Boston, Massachusetts, United States | Philadelphia, Pennsylvania, United States |
| Website | pathai.com | proscia.com |
Side by Side
Select any grade to read the note behind it.
Each vendor in one paragraph
Written to be quoted whole. Each paragraph opens the AI Health Index profile of the vendor: what the product is, who buys it and what it does.
Digital pathology company selling the AISight image management system and its own AI algorithms. AISight Dx is FDA 510(k) cleared (K243391, June 2025) for primary diagnosis with four named scanners and CE-IVD marked in Europe, and is deployed at laboratories including Labcorp and MedStar Health.
Source: AI Health Index, September 2026
Digital pathology software company whose Concentriq platform manages, displays and analyzes whole slide pathology images for clinical laboratories and life sciences organizations. Its diagnostic edition, Concentriq AP-Dx, is FDA 510(k) cleared (K230839 in 2024 and K261380 in August 2026, which added cloud deployment and a change control plan), Health Canada licensed and CE marked under the EU IVDR for primary diagnosis on FFPE surgical pathology slides; the research editions are labeled Research Use Only, a distinction the company draws explicitly.
Source: AI Health Index, September 2026
Questions buyers ask
How do PathAI and Proscia work with the EHR?
The image management pages say AISight is interoperable with most major laboratory information systems and with Hamamatsu, Leica, Roche and Philips scanners, and that AISight Link, PathAI's open API, powers LIS integration and embeds partner algorithms in the viewer. The pages name no LIS product, no standard such as HL7 or DICOM, and no integration documentation.
With Proscia, the company states that AI recommended ancillary test requests flow back into the LIS rather than a separate ticket queue, which is a real workflow closure rather than a display feature. The platform also serves as a host environment for third party algorithms, with at least one external spatial biology vendor embedding its predictive biomarker technology into Concentriq. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 28, 2026. No vendor pays for placement.
How do PathAI and Proscia handle patient data?
The privacy notice (effective 13 February 2025), which covers PathAI's platforms, says PathAI requests only the minimum information needed and retains it only as long as necessary to provide the services or for compatible purposes, including providing additional services.
For Proscia, the platform page states that "everything in Concentriq stays within your organization, unless you give express permission to de-identify and share it to advance research", and that "your data is never used to train the models Concentriq runs". From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 28, 2026. No vendor pays for placement.
Which settings and specialties do PathAI and Proscia cover?
With PathAI, the biomarker algorithms name their indications and supported antibody clones (PD-L1 in non-small cell lung, head and neck, melanoma and urothelial cancer; HER2, ER, PR and Ki-67 in breast), and the menu extends to ulcerative colitis and dermatopathology, but these are research use only in the United States with no validation named on the product pages.
In Proscia's case, the clinical edition serves high volume diagnostic laboratories for primary diagnosis on scanned surgical pathology slides from FFPE tissue, and excludes frozen sections, cytology and non-FFPE hematopathology specimens; the research editions serve life sciences organizations for biomarker research, clinical trials and companion diagnostics. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 28, 2026. No vendor pays for placement.
What evidence is published for PathAI and Proscia?
Pulaski and colleagues (Nature Medicine 2025, 31:315 to 322, open access, PathAI led) validated AIM-MASH on 1,481 liver biopsies from four completed global MASH trials with about 13,000 independent reads, testing the algorithm alone and as an aid against a consensus ground truth set by panels of hepatopathologists.
With Proscia, the earlier dermatopathology classifier was validated across two university hospitals and two commercial dermatopathology laboratories on more than 20,000 biopsy slides. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 28, 2026. No vendor pays for placement.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Digital Pathology AI page.
PathAI's Roche acquisition was still pending on its home page at review; ask how existing licensing and partner algorithms carry over. Neither publishes pricing. Rewritten 28 Sep 2026 after both records were reviewed.